Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06665100 · ClinicalTrials.gov registry record · Phase 2

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

A Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT), sponsored by Pulmotect.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
11
Study locations

NCT06665100 is a Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) that is actively recruiting participants, run by Pulmotect. The registered enrollment target is 100 participants, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06665100, a Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT), is actively recruiting participants, sponsored by Pulmotect.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.

Conditions Studied

Hematologic Malignancies Hematopoietic Stem Cell Transplant (HSCT)

Interventions

  • DRUG Placebo
  • DRUG PUL-042

Study Locations (11)

California

  • City of Hope National Medical Center - Duarte

Georgia

  • Northside Hospital - Atlanta

Maryland

  • Johns Hopkins Hospital - Baltimore

Massachusetts

  • Brigham and Women's Hospital - Boston

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit

Minnesota

  • University of Minnesota - Minneapolis

New Jersey

  • John Theurer Cancer Center - Hackensack

North Carolina

  • Lineberger Cancer - Chapel Hill

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-27
Est. Completion 2026-05
Phase Phase 2

Sponsor

Pulmotect

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06665100

The ClinicalTrials.gov registry entry for NCT06665100 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The listed sponsor is Pulmotect, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06665100 reports 11 study locations spanning 11 distinct geographic areas - top geographies include California, Georgia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06665100 about?

NCT06665100 is a clinical study titled "PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)". The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral ...

What is the current status of trial NCT06665100?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-27. Estimated completion is 2026-05.

What conditions does trial NCT06665100 study?

This clinical trial studies the following conditions: Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT).

What interventions are being tested in trial NCT06665100?

The interventions under investigation include: Placebo (DRUG), PUL-042 (DRUG).

Who is sponsoring clinical trial NCT06665100?

This trial is sponsored by Pulmotect, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06665100 being conducted?

This trial has 11 study locations across California, Georgia, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematologic Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hematologic Malignancies

All registered trials for this condition

Hematopoietic Stem Cell Transplant (HSCT)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.